PSCR (Proto Script Pharmaceutical) Piotroski F-Score: 0 (As of Aug. 04, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

What is Proto Script Pharmaceutical Piotroski F-Score?

The zones of discrimination were as such:

Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3

Proto Script Pharmaceutical has an F-score of 5 indicating the company's financial situation is typical for a stable company.

The historical rank and industry rank for Proto Script Pharmaceutical's Piotroski F-Score or its related term are showing as below:

Proto Script Pharmaceutical  (OTCPK:PSCR) Piotroski F-Score Explanation

The developer of the system is Joseph D. Piotroski is relatively unknown accounting professor who shuns publicity and rarely gives interviews.

He graduated from the University of Illinois with a B.S. in accounting in 1989, received an M.B.A. from Indiana University in 1994. Five years later, in 1999, after earning a Ph.D. in accounting from the University of Michigan, he became an associate professor of accounting at the University of Chicago.

In 2000, he wrote a research paper called "Value Investing: The Use of Historical Financial Statement Information to Separate Winners from Losers" (pdf).

He wanted to see if he can develop a system (using a simple nine-point scoring system) that can increase the returns of a strategy of investing in low price to book (referred to in the paper as high book to market) value companies.

What he found was something that exceeded his most optimistic expectations.

Buying only those companies that scored highest (8 or 9) on his nine-point scale, or F-Score as he called it, over the 20 year period from 1976 to 1996 led to an average out-performance over the market of 13.4%.

Even more impressive were the results of a strategy of investing in the highest F-Score companies (8 or 9) and shorting companies with the lowest F-Score (0 or 1).

Over the same period from 1976 to 1996 (20 years) this strategy led to an average yearly return of 23%, substantially outperforming the average S&P 500 index return of 15.83% over the same period.


Proto Script Pharmaceutical Piotroski F-Score Related Terms


Proto Script Pharmaceutical Piotroski F-Score Historical Data

* Premium members only.

The historical data trend for Proto Script Pharmaceutical's Piotroski F-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Proto Script Pharmaceutical Piotroski F-Score Chart

Proto Script Pharmaceutical Annual Data
Trend May12 May13 May14 May15 May16
Piotroski F-Score
0.00 0.00 4.00 2.00 0.00

Proto Script Pharmaceutical Quarterly Data
Nov12 Feb13 May13 Aug13 Nov13 Feb14 May14 Aug14 Nov14 Feb15 May15 Aug15 Nov15 Feb16 May16 Sep16 Dec16 Mar17 Jun17 Sep17
Piotroski F-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 6.00 0.00 0.00 0.00 4.00

How is the Piotroski F-Score calculated?

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

This Year (Sep17) TTM:Last Year (Sep16) TTM:
Net Income was -7.264 + -0.506 + -0.333 + -0.284 = $-8.39 Mil.
Cash Flow from Operations was 0.041 + -0.215 + -0.105 + -0.024 = $-0.30 Mil.
Revenue was 0.1 + 0.138 + 0.114 + 0.252 = $0.60 Mil.
Gross Profit was 0.001 + 0.107 + 0.03 + 0.214 = $0.35 Mil.
Average Total Assets from the begining of this year (Sep16)
to the end of this year (Sep17) was
(0.269 + 0.17 + 0.229 + 0.166 + 0.235) / 5 = $0.2138 Mil.
Total Assets at the begining of this year (Sep16) was $0.27 Mil.
Long-Term Debt & Capital Lease Obligation was $0.00 Mil.
Total Current Assets was $0.19 Mil.
Total Current Liabilities was $1.68 Mil.
Net Income was -0.008 + -0.002 + -0.021 + 0 = $-0.03 Mil.

Revenue was 0 + 0 + 0 + 0.214 = $0.21 Mil.
Gross Profit was 0 + 0 + 0 + 0.174 = $0.17 Mil.
Average Total Assets from the begining of last year (Aug15)
to the end of last year (Sep16) was
(0 + 0 + 0 + 0.012 + 0.269) / 5 = $0.1405 Mil.
Total Assets at the begining of last year (Aug15) was $0.00 Mil.
Long-Term Debt & Capital Lease Obligation was $0.00 Mil.
Total Current Assets was $0.25 Mil.
Total Current Liabilities was $0.29 Mil.

*Note: If the latest quarterly/semi-annual/annual total assets data is 0, then we will use previous quarterly/semi-annual/annual data for all the items in the balance sheet.

Profitability

Question 1. Return on Assets (ROA)

Net income before extraordinary items for the year divided by Total Assets at the beginning of the year.

Score 1 if positive, 0 if negative.

Proto Script Pharmaceutical's current Net Income (TTM) was -8.39. ==> Negative ==> Score 0.

Question 2. Cash Flow Return on Assets (CFROA)

Net cash flow from operating activities (operating cash flow) divided by Total Assets at the beginning of the year.

Score 1 if positive, 0 if negative.

Proto Script Pharmaceutical's current Cash Flow from Operations (TTM) was -0.30. ==> Negative ==> Score 0.

Question 3. Change in Return on Assets

Compare this year's return on assets (1) to last year's return on assets.

Score 1 if it's higher, 0 if it's lower.

ROA (This Year)=Net Income/Total Assets (Sep16)
=-8.387/0.269
=-31.17843866

ROA (Last Year)=Net Income/Total Assets (Aug15)
=-0.031/0
=

Proto Script Pharmaceutical's return on assets of this year was -31.17843866. Proto Script Pharmaceutical's return on assets of last year was . ==> This year is higher. ==> Score 1.

Question 4. Quality of Earnings (Accrual)

Compare Cash flow return on assets (2) to return on assets (1)

Score 1 if CFROA > ROA, 0 if CFROA <= ROA.

Proto Script Pharmaceutical's current Net Income (TTM) was -8.39. Proto Script Pharmaceutical's current Cash Flow from Operations (TTM) was -0.30. ==> -0.30 > -8.39 ==> CFROA > ROA ==> Score 1.

Funding

Question 5. Change in Gearing or Leverage

Compare this year's gearing (long-term debt divided by average total assets) to last year's gearing.

Score 0 if this year's gearing is higher, 1 otherwise.

Gearing (This Year: Sep17)=Long-Term Debt & Capital Lease Obligation/Average Total Assets from Sep16 to Sep17
=0/0.2138
=0

Gearing (Last Year: Sep16)=Long-Term Debt & Capital Lease Obligation/Average Total Assets from Aug15 to Sep16
=0/0.1405
=0

Proto Script Pharmaceutical's gearing of this year was 0. Proto Script Pharmaceutical's gearing of last year was 0. ==> This year is lower or equal to last year. ==> Score 1.

Question 6. Change in Working Capital (Liquidity)

Compare this year's current ratio (current assets divided by current liabilities) to last year's current ratio.

Score 1 if this year's current ratio is higher, 0 if it's lower

Current Ratio (This Year: Sep17)=Total Current Assets/Total Current Liabilities
=0.187/1.676
=0.11157518

Current Ratio (Last Year: Sep16)=Total Current Assets/Total Current Liabilities
=0.254/0.291
=0.87285223

Proto Script Pharmaceutical's current ratio of this year was 0.11157518. Proto Script Pharmaceutical's current ratio of last year was 0.87285223. ==> Last year's current ratio is higher ==> Score 0.

Question 7. Change in Shares in Issue

Compare the number of shares in issue this year, to the number in issue last year.

Score 0 if there is larger number of shares in issue this year, 1 otherwise.

Proto Script Pharmaceutical's number of shares in issue this year was 49.14. Proto Script Pharmaceutical's number of shares in issue last year was 330.48. ==> There is smaller number of shares in issue this year, or the same. ==> Score 1.

Efficiency

Question 8. Change in Gross Margin

Compare this year's gross margin (Gross Profit divided by sales) to last year's.

Score 1 if this year's gross margin is higher, 0 if it's lower.

Gross Margin (This Year: TTM)=Gross Profit/Revenue
=0.352/0.604
=0.58278146

Gross Margin (Last Year: TTM)=Gross Profit/Revenue
=0.174/0.214
=0.81308411

Proto Script Pharmaceutical's gross margin of this year was 0.58278146. Proto Script Pharmaceutical's gross margin of last year was 0.81308411. ==> Last year's gross margin is higher ==> Score 0.

Question 9. Change in asset turnover

Compare this year's asset turnover (total sales for the year divided by total assets at the beginning of the year) to last year's asset turnover ratio.

Score 1 if this year's asset turnover ratio is higher, 0 if it's lower

Asset Turnover (This Year)=Revenue/Total Assets at the Beginning of This Year (Sep16)
=0.604/0.269
=2.24535316

Asset Turnover (Last Year)=Revenue/Total Assets at the Beginning of Last Year (Aug15)
=0.214/0
=

Proto Script Pharmaceutical's asset turnover of this year was 2.24535316. Proto Script Pharmaceutical's asset turnover of last year was . ==> This year's asset turnover is higher. ==> Score 1.

Evaluation

Piotroski F-Score= Que. 1+ Que. 2+ Que. 3+Que. 4+Que. 5+Que. 6+Que. 7+Que. 8+Que. 9
=0+0+1+1+1+0+1+0+1
=5

Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3

Proto Script Pharmaceutical has an F-score of 5 indicating the company's financial situation is typical for a stable company.


Proto Script Pharmaceutical Business Description

Address 9830 6th Street, Suite 103, Rancho Cucamonga, CA, USA, 91730
Proto Script Pharmaceutical Corp is primarily in the business of repair power wheelchairs and scooters, which are classified as durable medical equipment (DME) products and reimbursable by healthcare insurance providers. It has various contracts with state and governmental insurance providers, among others. These contracts provide the company with the right to sell and repair DME and its health care insurance contracts allow it the ability to service patients nationally. The group currently has its presence of repair facilities in Las Vegas, Nevada, Rancho-Cucamonga, and Anaheim, California.